Exponent announces sale of BBI Group to Novo Holdings

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over £400 million.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents. Read more

Related Posts

Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming

Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...

24 March 2025

UNE retains R2 Research status, reinforcing leadership in scientific advancement

The University of New England has retained its status as one of the country’s leading research universities with the recent release...

23 March 2025

Maine college students investigate health effects of forever chemicals

Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...

21 March 2025